vTv's $77.2m cash is expected to last until diabetes drug trial reads out

vTv Therapeutics has told investors that its cash should carry it to the point where its pivotal type 1 diabetes study reports, and no further. The company ended the third quarter of 2026 with $77.2 million, and said that sum is expected to fund operations through the Phase 3 readout.

The readout concerns cadisegliatin. In results published on 5 November 2026, vTv said it had recruited its full cohort of 166 participants into CATT1, the Phase 3 trial. The company expects headline results around the middle of 2027. The update did not give a figure for spending beyond that date, so how any later commercial or development work would be paid for is not addressed.

Alongside the pivotal study, vTv has begun a Phase 2a trial of cadisegliatin in people who manage their diabetes with hybrid closed-loop insulin delivery systems. The move suggests the company is looking at how the drug might sit alongside automated insulin delivery, though the update gave no details of the study's design or timing.

Separately, the US Food and Drug Administration in October granted orphan designation to HPPD for sickle cell disease. By way of general context, the US designation is aimed at medicines for rare conditions and can carry development incentives, but it is not an approval and says nothing about whether a product works.